A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukaemia by disarming a gene that is responsible for tumour progression. That gene, known as Brg1 is a key regulator of leukaemia stem cells that are the root cause of the disease, resistance to treatment and relapse.

A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukaemia by disarming a gene that is responsible for tumour progression. That gene, known as Brg1 is a key regulator of leukaemia stem cells that are the root cause of the disease, resistance to treatment and relapse.

Julie Lessard, principal investigator and her colleagues at IRIC have spent the past four years studying that gene in collaboration with another research group at Stanford University in California. The results of this study are reported this week in the prestigious scientific journal Blood.

"When we removed the Brg1 gene, the leukaemia stem cells were unable to divide, survive and make new tumours. In other words, the cancer was permanently shut down", Lessard says.

One difficulty with targeting cancer stem cells is that many genes essential for their function are also essential for normal stem cells, and therapies targeting them can end up harming healthy stem cells as well. "Strikingly, we showed that the Brg1 gene is dispensable for the function of normal blood stem cells, making it a promising therapeutic target in leukaemia treatment" explains Pierre Thibault, principal investigator at IRIC and co-author in this study.

The story showed striking results on laboratory animals and human leukaemia cells but is still a long way from being transposed into the clinic. "The next step will be to develop a small-molecule inhibitor to successfully block Brg1 function in leukaemia, thus demonstrating the clinical relevance of this discovery", states Guy Sauvageau, chief executive officer and principal investigator at IRIC as well as clinical haematologist at the Hôpital Maisonneuve-Rosemont and co-author in this study.

The group is now performing experiments to identify such drugs that can disarm the Brg1 gene, thereby stopping leukaemia stem cells from generating malignant cells.

Cancer stem cells appear to be more resistant to radiotherapy and chemotherapy than the 'bulk' of the tumour and therefore, are often responsible for cancer relapse. As such, inhibiting residual leukaemia stem cells from dividing is the key to obtain irreversible impairment of tumour growth and long-term remission in patients. "Our recent studies identified the gene Brg1 as a regulator that governs the self-renewal, proliferative and survival capacity of leukaemia stem cells. Therefore, targeting the Brg1 gene in leukaemia stem cells may offer new therapeutic opportunities by preventing the disease from coming back", Lessard concludes.

Source: University of Montreal